Next Hydrogen Achieves Energy Efficiency Targets for its
MISSISSAUGA, Ontario, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Next Hydrogen Solutions Inc. (“Next Hydrogen”) (TSXV:NXH, OTC:NXHSF) is pleased to report that it...
Stay updated with breaking news from Sharon Chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MISSISSAUGA, Ontario, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Next Hydrogen Solutions Inc. (“Next Hydrogen”) (TSXV:NXH, OTC:NXHSF) is pleased to report that it...
Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE) ...
Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce...
Dupixent® sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review If approved, Dupixent would be the first and only treatment indicated in...
If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat ...